The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...
The US FDA has accepted Sun Pharmaceutical's supplemental Biologics License Application (sBLA) for ILUMYA, a treatment for ...
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...
Sun Pharmaceutical Industries Limited. Sun Pharma announces US FDA acceptance of supplemental Biologics License Application ...
If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe ...
Reset’s Melissa Schrumpf on everything you want to know about saunas, ice baths, LED light therapy, salt caves, steam rooms and compression boots but were too afraid to ask.
People with psoriasis prescribed bimekizumab have no greater risk for major depressive disorder or suicidal ideation than ...
Sun Pharmaceutical Industries Limited said on Monday, March 16, that the US Food and Drug Administration has accepted for ...
In phase 3 clinical trials, tildrakizumab treatment was associated with significantly higher ACR20 response rates at week 24 compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results